Articoli di riviste sul tema "636.408 9"
Segui questo link per vedere altri tipi di pubblicazioni sul tema: 636.408 9.
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Vedi i top-50 articoli di riviste per l'attività di ricerca sul tema "636.408 9".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Vedi gli articoli di riviste di molte aree scientifiche e compila una bibliografia corretta.
1
Oliveira, Leandro, Thais Megid, Daniela Rosa, Daniele Assad-Suzuki, Daniel Argolo, Solange Sanches, Laura Testa et al. "Abstract PO2-16-07: Real-world eligibility for adjuvant CDK4/6 inhibitors among patients without genomic risk for chemotherapy: a GBECAM multicenter retrospective study". Cancer Research 84, n. 9_Supplement (2 maggio 2024): PO2–16–07—PO2–16–07. http://dx.doi.org/10.1158/1538-7445.sabcs23-po2-16-07.
Abstract (sommario):
Abstract Background: Oncotype DX (ODX) is a genomic signature (GS) for the prediction of risk of recurrence and benefit of chemotherapy (CT) in both node negative (N0) and positive (N1), hormone receptor positive (HR+), HER2 negative (HER2-) early breast cancer (eBC). ODX was not an inclusion criterion in the MonarchE but was one in the Natalee study, in which trials most patients received neo-adjuvant chemotherapy. We aim to evaluate the proportion of patients potentially eligible for adjuvant CDK4/6 inhibitors (CDK4/6i) without CT indication by genomic risk using real-world data from a large dataset of patients from various Brazilian institutions. Methods: Clinicopathologic and ODX information were reviewed for patients with T1-T3, N0-N1, HR+/HER2- eBC who had an ODX performed between 2005 and 2020. Projections of CT indication by genomic criteria were based on TAILORx and RxPONDER data. Projections of adjuvant CDK4/6i indication were based on the MonarchE and Natalee criteria. Results: Of 636 patients, 27.5%/51.8%/20.8% were T1mic-a-b/T1c/T2-3, respectively. 19.5% were grade 1 (G1), 66.9% G2 tumors and 12.9% G3. 74 (11.6%) were N1. The ODX indicated low (< 11), intermediate (11-25) and high ( >25) risk in 117 (18.4%), 408 (64.1%) and 111 (17.5%) patients, respectively. 408 patients (64.2%) had low clinical risk and 228 patients (35.8%) had high clinical risk disease. In the overall cohort, 439 (69%) did not have genomic indication for CT, 25 (3.9%) and 133 (21%) were eligible for adjuvant abemaciclib and ribociclib, respectively. Among patients eligible for adjuvant CDK4/6i, greater than 50% did not meet genomic criteria for recommendation of CT (Table 1). Conclusions: In times of rapid incorporation of both GES (as valuable treatment de-escalation tools) and adjuvant CDK4/6i, our results suggest that a meaningful proportion of patients could be eligible for adjuvant abemaciclib and/or ribociclib independently of CT indication. However, little is currently known about the role of these agents in patients not treated with chemotherapy because they were largely unrepresented in these studies. Proportion of patients eligible for adjuvant CDK4/6i in the overall and non-CT eligible population. CT: chemotherapy Citation Format: Leandro Oliveira, Thais Megid, Daniela Rosa, Daniele Assad-Suzuki, Daniel Argolo, Solange Sanches, Laura Testa, José Bines, Rafael Kaliks, Débora Gagliato, Romualdo Barroso-Sousa, Tatiana Correa, Andrea Shimada, Daniel Batista, Daniel Musse, Marcelle Cesca, Débora Gaudêncio, Larissa Moura, Julio Araujo, Renata Colombo Bonadio, Artur Katz, Max Mano. Real-world eligibility for adjuvant CDK4/6 inhibitors among patients without genomic risk for chemotherapy: a GBECAM multicenter retrospective study [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO2-16-07.
2
Bell, John. "European Public Law. By Patrick Birkinshaw: [London: Butterworths, 2003. liv + 637 pp. ISBN 0-406-94266-9. £29.95]". International and Comparative Law Quarterly 53, n. 1 (gennaio 2004): 250–52. http://dx.doi.org/10.1093/iclq/53.1.250.
3
Liu, Wen-Hu, Yi-Shen Qiu, Hong-Jun Zhang, Jian-Hua Dai, Peng-Ye Wang e Liang-Ying Xu. "Energy transfer in Sr0.56Ba0.44Nb2O6:Ce AT 633 nm". Optics Communications 64, n. 1 (ottobre 1987): 81–84. http://dx.doi.org/10.1016/0030-4018(87)90374-9.
4
Sperling, Joy. "Dressed for Freedom: The Fashionable Politics of American Feminism, Einav Rabinovitch-Fox (2021)". Fashion, Style & Popular Culture 9, n. 3 (1 luglio 2022): 418–22. http://dx.doi.org/10.1386/fspc_00137_5.
Abstract (sommario):
Review of: Dressed for Freedom: The Fashionable Politics of American Feminism, Einav Rabinovitch-Fox (2021)Urbana, IL, Chicago, IL and Springfield, IL: University of Illinois Press, 248 pp.,ISBN 978-0-25204-401-4, h/bk, $110.00ISBN 978-0-25208-606-9, p/bk, $24.95ISBN 978-0-25205-294-1, e-book, $14.95
5
Nicolini, F. E., F. X. Mahon, J. Guilhot, A. Buzyn, M. Tulliez, C. Berthou, B. Christian, D. Guyotat, C. Preudhomme e F. Guilhot. "A phase III study exploring various doses of imatinib (IM) or IM in combination for newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML) patients (pts): Results of an interim analysis of the SPIRIT trial of French CML group". Journal of Clinical Oncology 27, n. 15_suppl (20 maggio 2009): 7058. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.7058.
Abstract (sommario):
7058 Background: IM 400 mg daily is the front-line treatment of CP CML, but provides only 50% major molecular responses (MMR) at 18 months (Mo). We designed a phase III randomized multicenter open-label prospective trial comparing IM 400 mg/d (n=159) with 3 experimental arms: IM 600 mg/d (n=160), IM 400 mg/d + s/c cytarabine (Ara-C), (20 mg/m2/d, d15–28 of 28-day cycles) (n=158) and IM 400 mg/d + s/c Peg-IFN2a (90 μg/wk) (n=159). Pts were allocated at a 1.1.1.1 ratio, stratified by Sokal risk groups. Molecular assessments were centralized and blinded. An interim analysis of 636 pts was planned based on an IS BCR-ABL/ABL ratio <0.01% (Optimal Molecular Response, OMR) at 1 year (α=0.85%, β=10%). Results: 636 pts were recruited between 9/2003 and 10/2007, median age 51 (18–78) yrs, 62% males, median follow-up for alive pts 36 (12–62) Mo. At 3 Mo, 88% of pts achieved complete hematologic response. Complete cytogenetic response (CCyR), MMR and OMR rates are presented (Table). MMR rates at 6 and 12 Mo were higher for IM-PegIFN as compared to IM-400 (p<10-3). At 18 Mo the cumulative OMR rates were 22% (IM-400), 28% (IM-600), 25% (IM-Ara-c), 43% (IM-PegIFN). Grade 3/4 neutropenia and/or thrombocytopenia occurred during the first year in 8% IM-400, 14% IM-600, 41% IM-Ara-C and 40% IM-PegIFN arms respectively. Grade 3/4 non-hematological toxicities occurred in 19% IM-400 (edemas, muscle cramps), 30% IM-600, 27% IM-Ara-C (diarrhea) and 31% IM-PegIFN pts (skin rashes, asthenia). Within the first 12 Mo, discontinuation of experimental treatment occurred in 8% IM-600, 39% Ara-C and 45% PegIFN pts. Conclusions: Although a significant number of pts reduced or stopped PegIFN within the first year, significant improvements in molecular response rates were observed in the IM-Peg IFN arm and may translate into survival benefit. [Table: see text] [Table: see text]
6
Li, Jian, e Zhihong Jeff Xia. "Mean plane of the Kuiper belt beyond 50 AU in the presence of Planet 9". Astronomy & Astrophysics 637 (maggio 2020): A87. http://dx.doi.org/10.1051/0004-6361/202037728.
Abstract (sommario):
Context. A recent observational census of Kuiper belt objects (KBOs) has unveiled anomalous orbital structures. This has led to the hypothesis that an additional ∼5 − 10 m⊕ planet exists. This planet, known as Planet 9, occupies an eccentric and inclined orbit at hundreds of astronomical units. However, the KBOs under consideration have the largest known semimajor axes at a > 250 AU; thus they are very difficult to detect. Aims. In the context of the proposed Planet 9, we aim to measure the mean plane of the Kuiper belt at a > 50 AU. In a comparison of the expected and observed mean planes, some constraints would be put on the mass and orbit of this undiscovered planet. Methods. We adopted and developed the theoretical approach of Volk & Malhotra (2017, AJ, 154, 62) to the relative angle δ between the expected mean plane of the Kuiper belt and the invariable plane determined by the eight known planets. Numerical simulations were constructed to validate our theoretical approach. Then similar to Volk & Malhotra (2017, AJ, 154, 62), we derived the angle δ for the real observed KBOs with 100 < a < 200 AU, and the measurement uncertainties were also estimated. Finally, for comparison, maps of the theoretically expected δ were created for different combinations of possible Planet 9 parameters. Results. The expected mean plane of the Kuiper belt nearly coincides with the said invariable plane interior to a = 90 AU. But these two planes deviate noticeably from each other at a > 100 AU owing to the presence of Planet 9 because the relative angle δ could be as large as ∼10°. Using the 1σ upper limit of δ < 5° deduced from real KBO samples as a constraint, we present the most probable parameters of Planet 9: for mass m9 = 10 m⊕, orbits with inclinations i9 = 30°, 20°, and 15° should have semimajor axes a9 > 530 AU, 450 AU, and 400 AU, respectively; for m9 = 5 m⊕, the orbit is i9 = 30° and a9 > 440 AU, or i9 < 20° and a9 > 400 AU. In this work, the minimum a9 increases with the eccentricity e9 (∈[0.2, 0.6]) but not significantly.
7
Kutluk, M. Tezer, e Akif Yeşilipek. "Pediatric Cancer Registry in Turkey 2009-2021 (TPOG & TPHD)." Journal of Clinical Oncology 40, n. 16_suppl (1 giugno 2022): e22020-e22020. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e22020.
Abstract (sommario):
e22020 Background: The pediatric cancers is in the global agenda to improve the survival rates which is still low in LMICs although it is more than 80% in HICs. More than 300.000 pediatric cancer cases annually are expected in children and adolescents aged 0-14 globally. Registry is the first step of an efficient cancer control. Here, we present the most updated results of the pediatric cancer registry fromTurkey. Methods: Turkish Pediatric Oncology Group and Turkish Pediatric Hematology Association has established the pediatric cancer registry in 2002. The childhood cancer cases registered between 2009-2021 was included in this analysis. International Childhood Cancer Classification System was used for the classification. Essential demographic findings, ICD-O-3 morphology and topography codes were recorded for each case. Results: During the 13 years from 2009 to 2021, 24080 cases were registered. For all cases, median age was 6.7 year (0-19; M/F 13461/10609, 4 hermaphrodite, 6 unknown). Age distribution was 0-4 yrs, 40.8%; 5-9 yrs, 23.8%; 10-14 yrs, 23.3%; 15-19 yrs, 12.1%) The distribution of the tumor types were [number of cases, percentage of total, median age yrs, M/F]: Leukemia (5819, 24.2%, 5.5, 3366/2453); Lymphoma & other RES tumors (4446, 18.5%, 9.8, 2956/1487, 1 hermaphrodite & 2 unknown); CNS [brain & spinal] (3730, 15.5%, 6.8, 2061/1668, 1 unkown); Symphatetic system (1965, 8.2%, 2.3, 1010/955); Retinoblastoma (675, 2.8%, 1.4, 375/300); Renal (1160, 4.8%, 3.1, 557/601, 1 hermaphrodite & 1 unknown); Liver (409, 1.7%, 2.2, 234/175); Malignant bone (1584, 6.6%, 12.6, 864/720); Soft tissue sarcomas (1726, 7.2%, 7.7, 983/743); Germ cell (1593, 6.6%, 9.6, 588/1001, 2 hermaphrodite, 2 unknown); Carcinoma & other malignant epithelial (804, 3.3%, 13.5, 381/423); Other/non-specific malignant (169, 0.7%, 7.9, 86/83). Five year survival rate was found as 72.3%. Conclusions: The registry shows that the survival rates for children and adolescents have been improved to 72% which reflects the status of the pediatric cancer care in Turkey. The data from this work became a valuable source for all stakeholders in national and international level working on improvement the pediatric cancer control.
8
Guilhot, Francois, François-Xavier Mahon, Joelle Guilhot, Francoise Rigual-Huguet, Frederic Maloisel, Philippe Rousselot, Martine Gardembas et al. "Randomized Comparison of Imatinib Versus Imatinib Combination Therapies in Newly Diagnosed Chronic Myeloid Leukaemia (CML) Patients in Chronic Phase (CP): First Results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC)". Blood 112, n. 11 (16 novembre 2008): 183. http://dx.doi.org/10.1182/blood.v112.11.183.183.
Abstract (sommario):
Abstract Imatinib (IM) at 400 mg daily is the first line therapy for newly diagnosed CML patients (pts); however, less than 50% of major molecular responses (MMR) are obtained at 12 months. To improve these results, we designed a phase III, multicenter, open-label, prospective randomized trial. The reference arm was IM 400 mg daily (n=159). The 3 experimental arms were IM 600 mg daily (n=160), IM 400mg daily in combination with Ara-C, (20 mg/m2/day, days 15–28 of 28-day cycles)(n=158) and IM 400mg in combination with Peg-IFN alfa-2a (Peg-IFN2a, 90 μg weekly) (n=159). Treatment was delivered at least 12 months or until treatment failure (disease progression) or major toxicity. The primary endpoint is the overall survival. Other endpoints are: rate and duration of hematologic and cytogenetic responses, major (MCyR) and complete (CCyR), molecular response (major molecular response ie MMR) and the tolerability. Using treatment allocation ratio 1.1.1.1, randomization was stratified according to Sokal risk groups. The current interim analysis of the first 636 patients (α=0.85%, β=10%) at 1 year from randomization was planned in order to select the best experimental arm for further comparison with IM 400. The increased dose of IM or a combination regimen would be considered as promising if it increased the 4 log reduction response rate by at least 20 percentage points, e.g. from 15% to 35%, with an acceptable tolerability. Evaluation of molecular response up to 12 months was centralized, blinded and calculated according to International score (IS). Pts were recruited between 9/2003 and 10/2007.[median age 51 yrs (18–82), 62% of pts were male; Sokal distribution was low risk 33%, intermediate risk 41% and 27% high risk]. Median follow-up is 36 months (range 8–57) at the time of analysis. Overall, at 3 months 86 % of pts achieved complete hematologic response. The MCyR, CCyR and MMR rates at 6 and 12 months are: IM-400 IM-600 IM-Ara-c IM-PegIFN *p< 10−2 (overall); ** p<10−2 (overall) At 6 months (636 pts, ITT) MCyR 74% 79% 68% 74% CCyR * 48% 67% 55% 56% At 12months (562 evaluable pts) MCyR 64% 76% 77% 74% CCyR 57% 65% 66% 71% MMR at 6 months** 21% 33% 27% 39% MMR at 12 months 40% 52% 51% 61% Interestingly the rate of MMR at 6 months was significantly higher for IM-PegIFN as compared with IM-400 (p<10−3). The 4-log reduction rate in the BCR-ABL/ABL transcript were 18%, 21%, 22%, 34%, for the IM-400, IM-600, IM-Ara-c and IM-PegIFN arms respectively. The corresponding numbers of undetectable (complete molecular response) pts were 2%, 2%, 3% and 9% at 12 months respectively. Grade 3/4 neutropenia and/or thrombocytopenia occurred in 8% of IM-400 pts, in 14% of IM-600 pts, in 41% of IMAra- c pts and in 40% of IM-PegIFN pts respectively. Grade 3/4 non hematological events were reported in 19% of IM-400 pts, in 30% of IM-600 pts, in 27% of IM Ara-c pts and in 31% of IM-PegIFN pts. Among them a relationship between treatment and event was suspected for 21 pts (13%) with IM-400 (7 liver toxicity; 7 oedema+muscle cramps), for 31 pts (19%) with IM-600 (7 liver toxicity, 11 oedema+ muscle cramps) for 36 pts (23%) with IM-Ara-c (2 liver toxicity; 10 gut side effect) and for 47 pts (29%) with IM-PegIFN (6 liver toxicity, 13 skin rash). Discontinuation of experimental treatment occurred within the first 6 and 12 months in 26% and 18% of IM-Ara-c pts and in 35% and 11% pts of IM-PegIFN pts respectively. Within the first 12 months 36% of 600-IM pts reduced their dosage. Although a substantial number of pts stopped PegIFN, this first analysis indicates the usefulness of a combination of IM-PegIFN for the initial treatment of pts with CML CP with a significant molecular response rate improvement. Complete analysis of the 636 pts with a follow-up of 12 months will be presented.
9
Khasanah, Nur, Raehanah, Bunawas, I. Wayan Ari M, Rinarto Subroto, Lalu Sahrul H, Paramita Putri A e Dia Ulfariah. "Measurement and Risk Analysis of Ozone (O3) Concentrations in the 9 MeV and 12 MeV Electron Mode LINAC". Jurnal Penelitian Pendidikan IPA 10, n. 2 (25 febbraio 2024): 757–63. http://dx.doi.org/10.29303/jppipa.v10i2.5347.
Abstract (sommario):
This study investigates potential non-radiation hazards, specifically Ozone (O3) production, during Linear Accelerator (LINAC) electron mode radiotherapy. The research uses experimental measurements to determine Ozone concentration in the LINAC patient waiting room and control room. Measurements are taken assuming a ±2-hour delay in one working day, using 9 MeV and 12 MeV energy, 400 MU dose rate, and illumination angles of 0o, 90o, and 270o. Maximum Ozone concentrations in the LINAC patient waiting room and control room are found to be 6.6 ppb (12 MeV) and 8.3 ppb (12 MeV), respectively. These concentrations fall below the chemical threshold limit and are deemed safe for human exposure. Notably, potentially detectable Ozone levels are observed in the LINAC banker. Overall, this research highlights the importance of monitoring Ozone levels to ensure the safety of both patients and personnel in LINAC facilities.
10
HUANG, Ming-li, Hong-xiao LI, Hua DING, Li BAO, Xiao-bin MA e Shi-ming HAO. "Intermetallics and phase relations of Mg-Zn-Ce alloys at 400 °C". Transactions of Nonferrous Metals Society of China 22, n. 3 (marzo 2012): 539–45. http://dx.doi.org/10.1016/s1003-6326(11)61211-9.
11
Xiong, Jiankun, Ting Li, Xinjian Yuan, Guijun Mao, Jianping Yang, Lin Yang e Jian Xu. "Improvement in Weldment of Dissimilar 9% CR Heat-Resistant Steels by Post-Weld Heat Treatment". Metals 10, n. 10 (2 ottobre 2020): 1321. http://dx.doi.org/10.3390/met10101321.
Abstract (sommario):
The effect of the post-weld heat treatment on the microstructures and mechanical properties of the dissimilar joint of G115, a novel developed martensite heat resistant steel, and CB2 steel, currently used in an ultra-super-critical power unit, was investigated. The results indicate that the quenched martensite underwent decomposition and transformation, and the amount of dislocations were sharply decreased in the weld metal after post-weld heat treatment (PWHT). Many nano-scale M23C6 precipitates present in the weldment were distributed on the grain and grain boundary in a dispersed manner with PWHT. The average microhardness of the weldment decreased from about 400 HV to 265–290 HV after PWHT and only a slight decrease in the microhardness of CB2 steel was detected after PWHT at 760 °C. In contrast to the case of the as-received joint, the tensile strength of the joint was improved from 630 MPa to 694 MPa and the fracture location moved from the weld metal to the base metal after PWHT. The fracture surface consisted of a cleavage fracture mode without PWHT, whereas many dimples were observed on the fracture surface with PWHT.
12
Brouwers, Elisabeth M., e Richard M. Forester. "Synonymies of Leptocythere klutinensis Forester and Brouwers, 1985, and Cytheromorpha knikensis Forester and Brouwers, 1985". Journal of Paleontology 67, n. 1 (gennaio 1993): 158. http://dx.doi.org/10.1017/s0022336000021338.
Abstract (sommario):
Dr. E. I. Schornikov (Institute of Marine Biology, Far East Branch, Academy of Sciences of Russia, Vladivostok) has kindly sent comparative specimens informing us that two of our species described from the Gulf of Alaska are junior synonyms of species that Schornikov described in 1974. Leptocythere klutinensis Forester and Brouwers, 1985, p. 364–366, figures 4.1–4.8, 7.6 is a junior synonym of Leptocythere polymorpha Schornikov, 1974, p. 155–157, text-figure 10, Plate 2, figure 3. Cytheromorpha knikensis Forester and Brouwers, 1985, 357–362, figures 5.1–5.8, 6.3–6.6, 7.1–7.2, is a junior synonym of Cytheromorpha lagunae Schornikov, 1974, 153–155, text-figure 9.
13
Maloisel, F., V. Dubruille, B. Varet, M. Escoffre-Barbe, P. Berthaud, V. Meresse, F. Mahon, C. Preudhomme, J. Guilhot e F. Guilhot. "Design and first interim analysis of a randomized phase III trial comparing imatinib versus imatinib (IM) based combination therapies in newly diagnosed chronic myelogenous leukemia patients in chronic phase". Journal of Clinical Oncology 24, n. 18_suppl (20 giugno 2006): 6589. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.6589.
Abstract (sommario):
6589 Background: Despite impressive results achieved with IM 400 mg/day alone, only a minority of pts reached a complete molecular remission at 12-month. Higher dose of IM or its combination with other therapies might improve molecular remission. Design of the trial: the 3 experimental arms are IM 400mg daily in combination with Peg-IFN-α2a (Peg-IFNα2a, 90 μg weekly) or with Ara-C (20 mg/m2/day, days 15–28 of 28-day cycles) or IM 600mg daily. The reference arm is IM 400mg daily. All pts (over 18 years of age with Bcr-Abl positive CML) receive IM 400 mg/day as monotherapy days 1–14 and then start the assigned regimen for at least 12 months. The endpoints are overall survival (primary), rate and duration of hematologic, cytogenetic and molecular responses and tolerability. An interim analysis of the first 636 pts at 1 year from randomization will allow evaluation of molecular response rates, one of the experimental arm being selected for further comparison with IM 400. An experimental arm would be selected if it increased the 4 log reduction response rate at 12-month by at least 20 percentage points, (15% to 35%), with an acceptable tolerability. Results: This evaluation is based on a cohort of 370 pts with a median time of observation of 16 months, recruited between 9/2003 and 9/2005. [median age 53 yrs (18–81); Sokal distribution: 38% of pts low, 38% intermediate, and 24% high]. At 1 month 80% of pts achieved complete hematologic response. At 12 months, 138 pts (72%) achieved a major cytogenetic response, being complete in 120 pts (63%). Grade 3/4 hematologic toxicity occurred in 8% of IM400 pts, 9% of IM600 pts, 41% of IM+IFN pts and 33% of IM+Ara-c pts respectively. Dose of Peg IFN was reduced in 16% of pts, 45 μg per week being well tolerated. Grade 3/4 non hematological toxicity occurred in 11% of IM400 pts, 16% of IM600 pts, 10% of IM+IFN pts (maily skin rash) and 11% of IM+Ara-c pts. Discontinuation of experimental treatment occurred in 17% of IM600 pts, 36% of IM+IFN pts and 16% of IM+Ara-c pts. Conclusion: This first analysis confirmed both feasibility of IM combinations and high response rates. However a substantial hematological toxicity requires a careful assessment of pts. [Table: see text]
14
Lubis, Aridamuriany D., Syahril Pasaribu, Muhammad Ali e Munar Lubis. "Effect of length of albendazole treatment against Trichuris trichiura infection". Paediatrica Indonesiana 53, n. 5 (8 settembre 2016): 245. http://dx.doi.org/10.14238/pi53.5.2013.245-9.
Abstract (sommario):
Background Trichuris trichiura is one of the most common soil-transmitted helminth that infects school-aged children. A single dose of albendazole has been shown to have wide variations in cure and egg reduction rates. Some studies have suggested that repeated doses of albendazole might increase its effectiveness.Objective To compare the anti-trichuriasis effect of 400 mg albendazole taken daily for five consecutive days vs. seven consecutive days.Methods A randomized open clinical trial was conducted from August to September 2009 on elementary school children at Jaring Halus in the North Sumatera Province. Stool specimens were collected before treatment and on days 7, 14, 21, and 28 after initiation of treatment, and examined by the Kato Katz method. Subjects were randomized into two groups. Group I received 400 mg albendazole daily for five consecutive days and Group II received 400 mg albendazole daily for seven consecutive days. Cure rates and egg reduction rates were compared using Chi-square and T-tests, respectively.Results One hundred twenty-one children were enrolled, consisted of 61 children in Group I and 60 in Group II. For the first week after treatment ended, the cure rates in Group II was higher (86.7%) than in the Group I (39.3%) (P=0.001), as well as in the second week after treatment ended (88.3% vs 68.9%, P=0.017). However, after 3rd and 4th weeks, the cure rates were no longer significantly different. Egg reduction rate was also statistically higher in the Group II [20.3 (SD 23.77) %] compared to Group I [6.6 (SD 11.30) %].Conclusions Albendazole for seven consecutive days is more effective in curing Trichuris trichiura infection in the 1st and 2nd weeks after treatment compared to that of five consecutive days, as well as in egg reduction rate, but the length of treatment does not influence the cure rate after the 3rd and 4th weeks.
15
Mueller, Andreas G., David I. Groves e Claude P. Delor. "The Savage Lode magnesian skarn in the Marvel Loch gold–silver mine, Southern Cross greenstone belt, Western Australia. Part 2: Pressure–temperature estimates and constraints on fluid sources". Canadian Journal of Earth Sciences 28, n. 5 (1 maggio 1991): 686–705. http://dx.doi.org/10.1139/e91-060.
Abstract (sommario):
The Savage Lode gold skarn orebody in the Marvel Loch mine, Southern Cross greenstone belt, Western Australia, replaces foliated metakomatiites in a subvertical ductile shear zone, and is located within the broad metamorphic aureole of the Ghooli Dome granodiorite–granite batholith. Pressure estimates based on metamorphic as well as alteration mineral parageneses indicate that skarn formation took place at P = 4 ± 1 kbar (1 kbar = 100 MPa), corresponding to a burial depth of about 13 km. Metamorphism reached temperatures of 550–630 °C in the mine area, and preceded skarn formation.Pressure–temperature calculations constrain the maximum temperature of the hydrothermal fluid in the Savage Lode to 640 ± 20 °C during the formation of early olivine–calcite and diopside–amphibole rocks, and to 500–600 °C during the formation of phlogopite–chlorite–calcite schists and quartz–diopside veins. Lower fluid temperatures (500 to ~ 400 °C) are recorded by retrograde serpentine (after olivine), talc (after tremolite), and petrographically late aggregates of muscovite + clinozoisite + prehnite. The oxygen fugacity of the fluid is estimated at 10−20–10−24 bar (1 bar = 100 kPa), based on the assemblage magnetite + ilmenite + olivine in calcite-rich prograde skarn. The sulphur fugacity of the fluid is estimated at 10−7–10−9 bar, based on the assemblages pyrrhotite + loellingite, pyrrhotite + arsenopyrite and pyrite + marcasite, which were deposited in a retrograde régime, when fluid temperatures fell from 550 to < 400 °C.The isotopic composition of the fluid (206Pb/204Pb = 13.77, 87Sr/86Sr = 0.7024, δ13C = −4.8‰), as inferred from hydrothermal galena, scheelite, and calcite, indicates equilibration at high temperatures with rocks of granodioritic or granitic composition. Late syn- to post-mineralization pegmatite dykes, exposed in the present mine workings, provide evidence for magmatic activity at depth. The Marvel Loch deposit represents the first well-described example of an Archean gold skarn system.
16
Moningka, Mirabella V., Douglas N. Pareta, Hariyadi Hariyadi e Nerni Potalangi. "Formulasi Dan Uji Aktivitas Antibakteri Sediaan Sabun Cair Ekstrak Daun Pala Myristica fragrans Houtt". Biofarmasetikal Tropis 3, n. 2 (31 ottobre 2020): 17–26. http://dx.doi.org/10.55724/j.biofar.trop.v3i2.280.
Abstract (sommario):
Sabun cair merupakan campuran dari senyawa kalium dengan asam lemak yang digunakan sebagai bahan pembersih tubuh, berbentuk cair, busa, dengan atau tanpa zat tambahan lain serta tidak menimbulkan iritasi pada kulit. Tujuan penelitian ini untuk membuat sediaan sabun cair ekstrak daun pala dan melakukan pengujian aktivitas antibakteri sediaan sabun cair ekstrak daun pala terhadap bakteri S. aureus. Penelitian ini merupakan eksperimen laboratorium. Metode yang digunakan adalah difusi sumuran. Hasil penelitian menunjukkan sediaan sabun cair ekstrak daun pala memiliki aktivitas antibakteri ditandai dengan terbentuknya zona hambat. Dari hasil penelitian dapat disimpulkan bawah formulasi sediaan sabun cair ekstrak daun pala dengan konsentrasi 8% dan 9% telah memenuhi persyaratan yang sesuai dengan standar yang ditetapkan SNI 06-4085-1996. Sedangkan pada konsentrasi 10% dalam uji pH tidak memenuhi persyaratan. Formulasi sediaan sabun cair ekstrak daun pala memiliki aktivitas antibakteri terhadap bakteri Staphylococcus aureus yaitu pada konsentrasi 8% zona hambat 9.6 mm, konsentrasi 9% zona hambat 7.3 mm, dan konsentrasi 10% zona hambat 6.6 mm.
17
Cornely, Oliver A., David Helfgott, Amelia Langston, Werner Heinz, Jörg-Janne Vehreschild, Maria J. G. T. Vehreschild, Gopal Krishna, Lei Ma, Susan Huyck e Michael C. McCarthy. "Pharmacokinetics of Different Dosing Strategies of Oral Posaconazole in Patients with Compromised Gastrointestinal Function and Who Are at High Risk for Invasive Fungal Infection". Antimicrobial Agents and Chemotherapy 56, n. 5 (30 gennaio 2012): 2652–58. http://dx.doi.org/10.1128/aac.05937-11.
Abstract (sommario):
ABSTRACTThe aim of this study was to assess different dosing strategies that may result in increased posaconazole bioavailability in patients with compromised gastrointestinal function and at high risk for invasive fungal infections. Patients undergoing chemotherapy and at risk for compromised gastrointestinal function received open-label posaconazole at 200 mg three times daily (TID) on days 1 to 8. Patients were randomized to one of three open-label dosing regimens of posaconazole on days 9 to 15: 200 mg TID, 400 mg twice daily (BID), or 400 mg TID. The plasma concentrations of interest on days 8 and 15 were 500 and 700 ng/ml, respectively; day 2 plasma concentrations of 250 and 350 ng/ml were chosen as levels that might result in steady-state concentrations of >500 and >700 ng/ml, respectively. A total of 75 patients enrolled; 52/75 (69%) completed the study, and 49/75 were included in the pharmacokinetic analyses. Mean plasma concentrations were 230, 346, and 637 ng/ml on days 2, 3, and 8, respectively. The day 15 values were 660, 930, and 671 ng/ml for 200 mg TID, 400 mg BID, and 400 mg TID, respectively. In 12 patients with a day 8 posaconazole concentration of <250 ng/ml, an overall benefit of the higher two doses was not apparent, suggesting that a subset of patients has low steady-state plasma concentrations. A change in dosing regimen on day 9 did not lead to higher exposures in these “poor absorbers” on day 15. Poor absorption may be enhanced with a high-fat meal, a nutritional supplement, or acidification.
18
Tsai, Meng-Ko, Kuang-Chen Hung, Chun-Cheng Liao, Lung-Fa Pan, Chia-Lien Hung e Deng-Ho Yang. "The Association between Serum Testosterone and Hyperuricemia in Males". Journal of Clinical Medicine 11, n. 10 (12 maggio 2022): 2743. http://dx.doi.org/10.3390/jcm11102743.
Abstract (sommario):
Gout is a common systemic inflammatory disease with a male predominance. This study aimed to determine the relationship between serum total testosterone level and hyperuricemia. Data on 1899 men, collected from 2007 to 2017, were included in the analysis. Serum testosterone and urate (SU) were measured on enrolment. The primary endpoints were SU levels ≥ 7 mg/dL and ≥9 mg/dL. On enrolment, participants had a mean age of 45.6 years and mean total testosterone and SU levels of 510 ng/dL and 6.6 mg/dL, respectively. The mean total testosterone levels were 533 and 470 ng/dL in patients with SU levels < 7 mg/dL and ≥7 mg/dL, respectively (p < 0.001); and 515 and 425 ng/dL in patients with SU levels < 9 mg/dL and ≥9 mg/dL, respectively (p < 0.001). After adjusting for age, body mass index, creatinine, serum lipid, fasting blood glucose, systolic blood pressure, and diastolic blood pressure, low testosterone level (<400 ng/dL) was significantly associated with an SU level ≥ 7 mg/dL (hazard ratio: 1.182, 95% confidence interval: 1.005–1.39) and ≥9 mg/dL (hazard ratio: 1.905, 95% confidence interval: 1.239–2.928). In men, a low testosterone level may be associated with an increased risk of hyperuricemia.
19
WU, S., L. VAN ASTEN, L. WANG, S. A. MCDONALD, Y. PAN, W. DUAN, L. ZHANG et al. "Estimated incidence and number of outpatient visits for seasonal influenza in 2015–2016 in Beijing, China". Epidemiology and Infection 145, n. 16 (9 novembre 2017): 3334–44. http://dx.doi.org/10.1017/s0950268817002369.
Abstract (sommario):
SUMMARYInformation on morbidity burden of seasonal influenza in China is limited. A multiplier model was used to estimate the incidence and number of outpatient visits for seasonal influenza by age group for the 2015–2016 season in Beijing, the capital of China, based on reported numbers of influenza-like illness consultations and proportions of positive cases from influenza surveillance systems in Beijing, general consultation rates and other parameters from previous studies, surveys and surveillance systems. An estimated total of 1 190 200 (95% confidence interval (CI) 830 400–1 549 900) cases of influenza virus infections occurred in Beijing, 2015–2016 season, with an attack rate of 5·5% (95% CI 3·9–7·2%). These infections resulted in an estimated 468 280 (95% CI 70 700–606 800) outpatient visits, with an attack rate of 2·2% (95% CI 0·3–2·8%). The attack rate of influenza virus infections was highest among children aged 0–4 years (31·9% (95% CI 21·9–41·9%)), followed by children aged 5–14 years (18·7% (95% CI 12·9–24·5%)). Our study demonstrated a substantial influenza-related morbidity in Beijing, China, especially among the preschool- and school-aged children. This suggests that development or modification of seasonal influenza targeted vaccination strategies need to recognize that incidence is highest in children.
20
Lin, Shi-Ming, Chih-Hung Hsu, Long-Bin Jeng, Yih-Jyh Lin, Ming-Yang Lee, Teng-Yu Lee e Yi-Hsiang Huang. "Contemporary real-world evidence in unresectable HCC (uHCC) patients treated with regorafenib in Taiwan: Interim results from the observational REFINE study." Journal of Clinical Oncology 40, n. 4_suppl (1 febbraio 2022): 402. http://dx.doi.org/10.1200/jco.2022.40.4_suppl.402.
Abstract (sommario):
402 Background: The phase 3 RESORCE trial showed that regorafenib improved overall survival compared to placebo in uHCC patients (pts) who progressed on sorafenib. The characteristics of real-world pts are more diverse than those included in clinical trials. The global observational REFINE study was designed to evaluate the safety and effectiveness of regorafenib in pts with uHCC in a real-world setting. Methods: REFINE is an ongoing observational study of pts with uHCC who were treated with regorafenib in routine practice. The primary end point includes to assess treatment-emergent adverse events (TEAEs; NCI-CTCAE v4.03). Secondary endpoints include overall survival, progression-free survival, and tumor response. Tumor response and progression are assessed per investigator according to local standard. A planned interim analysis of 1008 pts in the global cohort has been reported (Lim, ILCA 2021). We describe interim results in pts from Taiwan. Results: A total of 137 pts were enrolled and 136 were valid for safety analysis (80% male). At study entry, median age was 65.5 years (Q1-Q3, 60-72); 51.5% pts had an ECOG PS 0 and 24.3% and 12.5% had an ECOG PS of 1 and, respectively (missing 11.8%); proportion of pts classified as Child–Pugh A/B/C were 46.3%/10.3%/0.7% (missing/not evaluable: 40.4%/2.2%). The initial daily regorafenib dose was 160 mg in 8% of pts and 120 mg/80 mg in 9%/78%; 5.1% started at 40 mg. 83.1% pts received regorafenib as a second line agent and 15.4% pts as third line or beyond. 132 pts had prior sorafenib treatment with last daily dose being 400mg in 53.8% of patients; 9 patients (6.6%) had received an immune checkpoint inhibitor. The most frequent TEAEs are shown (Table). Effectiveness results will be presented. Conclusions: The characteristics of real-world pts from Taiwan not only differ from those in the RESORCE trial but also from the global REFINE cohort, reflecting variation across countries. A higher proportion of patients from Taiwan initiated regorafenib at a lower dose. Clinical trial information: NCT03289273. [Table: see text]
21
Maron, Steven Brad, Walid Khaled Chatila, Henry S. Walch, Ryan Ptashkin, Shalom Sabwa, Lilan Ling, Rebecca Nagy et al. "Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer." Journal of Clinical Oncology 39, n. 15_suppl (20 maggio 2021): 4058. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.4058.
Abstract (sommario):
4058 Background: Pembrolizumab and trastuzumab (P&T) and chemotherapy demonstrated 27 month mOS, 13 month mPFS, and 91% response rate in first-line HER2-positive mEG cancer irrespective of PD-L1 status (Janjigian Lancet Oncology 2020). Biomarkers including 89Zr-trastuzumab PET, blood, and tumor analysis were correlated with progression-free survival. Methods: Twenty-five patients received P&T once 3 weeks prior to addition of chemotherapy to P&T. Pre-treatment tumor biopsies, 89Zr-trastuzumab PET scans, serial plasma ctDNA (Guardant360, Redwood City, CA) and CT scans were performed. Tumor-matched DNA alterations were identified by correlating ctDNA and tissue-NGS variant calls. Pre-, on-, and post-treatment biopsies were analyzed using WES and IHC (HER2, PD-L1). Biomarkers were correlated with mPFS and 6-month PFS, the primary endpoint. Results: Of patients with tumor-matched mutations ctDNA at baseline, 12 of 16 had a decline in their maxVAF by week 3, corresponding to a mPFS of 14.7 (11.0-NR) vs 5.9 (95% CI 4.1-NR) months (p=0.009) and a mOS of 29.7 (95% CI 27.2-NR) vs 7.71 (95% CI 6.6-NR) months (p=0.006). 9 of 12 (75%) patients with decline in ctDNA at 3 weeks post-P&T achieved the 6-month PFS primary endpoint while the 4 patients with no decline in ctDNA all progressed in under 6-months. Similarly, 7 of 9 (78%) patients who had a decline in CT-measurements in all disease sites achieved the 6 month PFS primary endpoint, versus 10 of 16 (62.5%) of patients who did not respond in all sites (p=0.66), suggesting that ctDNA is superior to CT as an early predictive biomarker of response. Lack of ERBB2 amplification (amp) by NGS in ctDNA and/or tumor was associated with lack of response to P&T alone prior to addition of chemotherapy. Interestingly, no lesions from patients lacking ERBB2 ctDNA amp (n=3) responded to induction P&T by CT, while lesions from 3/9 patients lacking ERBB2 tissue amp responded to P&T by 3-week CT, suggesting intrapatient HER2 heterogeneity. Eight patients also underwent 89Zr-Trastuzumab PET scans prior to P&T and up to 5 lesions per disease site were measured on serial CT scans. All 15 lesions with intense uptake (SUVmax>10) responded to P&T, but only 9/24 lesions with SUVmax<10. All 4 patients who had at least 1 intense lesion achieved a post-P&T CT response and later 6+ month PFS. All 3 of 3 evaluable patients with intense uptake had baseline ctDNA ERBB2 amp. Conclusions: Patients with a decline in tumor-matched maxVAF after one dose of P&T were more likely to achieve durable PFS. Pre-treatment ctDNA ERBB2 amp and/or intense 89Zr-trastuzumab PET avidity are non-invasive predictive biomarkers of response to HER2-directed therapy. Evaluation of tumor immune environment digital spatial profiling is underway. Clinical trial information: NCT02954536.
22
Belyakov, Andrey, Rustam Kaibyshev, Yuuji Kimura e Kaneaki Tsuzaki. "Recrystallization Mechanisms in Severely Deformed Dual-Phase Stainless Steel". Materials Science Forum 638-642 (gennaio 2010): 1905–10. http://dx.doi.org/10.4028/www.scientific.net/msf.638-642.1905.
Abstract (sommario):
The structural recrystallization mechanisms operating in an Fe – 27%Cr – 9% Ni dual-phase (ferrite-austenite) stainless steel after large strain processing to total strain of 4.4 were investigated in the temperature range of 400-700oC. The severe deformation resulted in the development of an ultrafine grained microstructure consisting of highly elongated grains/subgrains with transverse dimensions of 160 nm and 130 nm in ferrite and austenite, respectively. The annealing mechanism operating in ferrite phase was considered as continuous recrystallization, which involved recovery leading to the development of essentially polygonized microstructure. On the other hand, the mechanism of discontinuous nucleation took place at an early recrystallization stage in austenite phase.
23
Lange, S., T. Reich, J. Nowak, B. Dimov, M. Meister e E. Hennig. "Photo detector IC for Blu-ray-Disc applications: a realization applying efficient design methodologies". Advances in Radio Science 9 (1 agosto 2011): 219–23. http://dx.doi.org/10.5194/ars-9-219-2011.
Abstract (sommario):
Abstract. A high-speed photo detector IC for application in Blu-ray/DVD/CD drives is presented. Bandwidths for the highest gain of 254 MHz and 221 MHz for 405 nm (Blu-ray) and 635 nm (DVD) wavelengths, respectively, were achieved by applying novel design methodologies. The combination of this outstanding speed performance with its low power dissipation of 192 mW at 5V supply and the low noise power of −72 dBm at 300 MHz makes it the best in literature reported optical transceiver IC for Blu-ray and Blu-ray/DVD/CD multi drives. Beside the excellent performance results, the usage of the novel design methodologies gave us an increased design efficiency with 25% compared to earlier similar design processes.
24
Ribeiro, S., E. M. B. Santos, G. C. R. Garcia e J. A. Rodrigues. "Elastic Work and Fracture Energy of Concretes Made with Crushed Stones and Pebbles Aggregates". Materials Science Forum 636-637 (gennaio 2010): 1215–21. http://dx.doi.org/10.4028/www.scientific.net/msf.636-637.1215.
Abstract (sommario):
This work examines the elastic work and fracture energy of a mortar and two concretes using the wedge splitting method to attain stable crack propagation. A comparison was made of the fracture energy in mortar and concrete using two different aggregates: crushed stone and pebbles, both with sizes between 4.8 and 9.5 mm. The mortar was made of sand, Portland cement and water, using a cement: sand ratio of 1:2. The water content was 0.46 of the cement mass. The samples were molded and then cured for seven days at 25oC in 100% relative humidity. After curing, the samples were dried at 55oC for 48 hours. The concretes were produced using the same procedure, but with the addition of the aggregates. The amount of aggregate was 10 wt.% of the total weight of cement plus sand. After curing and drying, the samples were subjected to the wedge splitting procedure. The tests were carried out at a constant displacement rate of 0.030 mm/min. The following results were obtained: elastic work: 80.4 ± 0.6, 114 ± 9 and 110 ± 12 mJ, and fracture energy: 30.3 ± 0.6, 40 ± 1, and 40 ± 5 J.m-2, respectively, for the mortar and for the concretes containing crushed stone and pebbles. These results allow us to conclude that the aggregates improved the elastic work and the fracture energy of the concretes. However, the type of aggregate did not make any difference to the properties. These findings contradict what is generally known, i.e., “that concrete produced with pebbles is inferior to concrete made with crushed stone”, at least insofar as it concerns the energies associated with the fracture process.
25
Rini, Brian I., Bernard J. Escudier, M. Dror Michaelson, Sylvie Negrier, Martin Eric Gore, Stephane Oudard, Joseph Clark et al. "Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): Effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy." Journal of Clinical Oncology 30, n. 5_suppl (10 febbraio 2012): 354. http://dx.doi.org/10.1200/jco.2012.30.5_suppl.354.
Abstract (sommario):
354 Background: Axitinib is a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3. In the phase 3 AXIS trial of axitinib vs sorafenib for second-line mRCC, axitinib significantly prolonged median progression-free survival (mPFS) (6.7 vs 4.7 months; hazard ratio 0.665; P<0.0001). Here, we evaluated the effect of prior sunitinib treatment duration and axitinib dose titration on subsequent axitinib efficacy. Methods: Eligible patients had clear-cell mRCC; measurable RECIST-defined progressive disease after 1 prior first-line systemic therapy; and Eastern Cooperative Oncology performance status (PS) 0/1. Patients were stratified by PS and prior therapy, and randomized 1:1 to either axitinib, at a starting dose of 5 mg twice daily (BID), or sorafenib, 400 mg BID. Patients without toxicity >grade 2 and BP <150/90 mmHg without antihypertensive medication for >2 weeks were eligible to increase axitinib dose to 7 mg BID and then to 10 mg BID. Results: The mPFS for patients receiving at least one total daily axitinib dose >10 mg (dose-titrated group; n=132) was 6.6 months [95% CI 4.7–8.3] and 8.3 months [95% CI 6.0–10.2] for patients receiving axitinib ≤10 mg (n=227). A total of 194 patients (53.7%) in the axitinib arm and 195 patients (53.9%) in the sorafenib arm had prior sunitinib treatment. The mPFS for patients with duration of prior sunitinib treatment ≥6 months and <6 months were 4.8 months [95% CI 4.5–6.5] and 4.6 months [95% CI 2.8–8.3] for axitinib patients; and 4.6 months [95% CI 2.9–4.9] and 2.9 months [95% CI 2.8–4.6), for sorafenib patients. The mPFS for duration of prior sunitinib ≥9 months and <9 months were 6.3 months [95% CI 4.6–6.7] and 4.5 months [95% CI 2.8–6.4] for axitinib patients; and 4.6 months [95% CI 2.8–4.9] and 2.9 months [95% CI 2.8–4.7]) for sorafenib patients. Conclusions: Duration of prior sunitinib ≥9 months may be associated with a longer PFS on second-line VEGFR tyrosine kinase inhibitors. Both axitinib dose-increased and non-increased patients had longer PFS compared with the sorafenib arm.
26
Raade, G., T. Balić-Žunić e C. J. Stanley. "Byrudite, (Be,〈)(V3+,Ti)3O6, a new mineral from the Byrud emerald mine, South Norway". Mineralogical Magazine 79, n. 2 (aprile 2015): 261–68. http://dx.doi.org/10.1180/minmag.2015.079.2.05.
Abstract (sommario):
AbstractByrudite (IMA 2013-045, Raade et al., 2013), with simplified formula (Be,〈)(V3+,Ti)3O6, occurs in emerald-bearing syenitic pegmatites of Permian age at Byrud farm, Eidsvoll, Akershus, South Norway. It has a norbergite-type structure, Pnma, with a = 9.982(1), b = 8.502(1), c = 4.5480(6) Å, V = 385.97(9) Å3, Z = 4. The structure was refined to R1 = 0.045 for 1413 unique reflections. Twinning occurs on {210}. The occupancy of the tetrahedral Be site refined to 0.84(1). The presence of Be was verified by secondary ion mass spectrometry but could not be quantified. Electron-microprobe analyses of the crystal used for structure determination gave the empirical formula (Be0.84〈0.16) (V1.323+Ti1.25Cr0.29Fe0.09Al0.07)Σ3.02O6. There is a strong inverse correlation between V and Cr. The ideal endmember formula is BeV23+TiO6. The mineral is black and opaque with a metallic lustre. Reflectance data in air are reported from 400 to 700 nm. The Commission on Ore Mineralogy required wavelengths are [R1, R2(λ in nm)]:16.6,17.5(470), 16.7,17.9(546), 16.8,18.3(589) and 16.8,18.6(650). The Mohs hardness is ∼7, based on indentation measurements. The mineral is brittle with an uneven fracture; cleavage is not present. D(calc.) = 4.35 g cm–3 for the empirical formula with 0.84 Be a.p.f.u. The strongest reflections of the calculated powder X-ray diffraction pattern are [d in Å (Irel)(hkl)]: 3.721(72)(111), 2.965(100)(121), 2.561(50)(311), 2.464(41)(230), 2.167(24)(231), 1.681(34)(402), 1.671(66)(232), 1.435(23)(630).
27
Schindlbeck, Markus. "Penny, H. Glenn: Im Schatten Humboldts. Eine tragische Geschichte der deutschen Ethnologie. München: Verlag C. H. Beck, 2019. 287 pp. ISBN 978-3-406-74128-9. Preis: € 26,95". Anthropos 115, n. 2 (2020): 616–21. http://dx.doi.org/10.5771/0257-9774-2020-2-616.
28
Stylianakis, Minas M., Dimitrios M. Kosmidis, Katerina Anagnostou, Christos Polyzoidis, Miron Krassas, George Kenanakis, George Viskadouros, Nikolaos Kornilios, Konstantinos Petridis e Emmanuel Kymakis. "Emphasizing the Operational Role of a Novel Graphene-Based Ink into High Performance Ternary Organic Solar Cells". Nanomaterials 10, n. 1 (2 gennaio 2020): 89. http://dx.doi.org/10.3390/nano10010089.
Abstract (sommario):
A novel solution-processed, graphene-based material was synthesized by treating graphene oxide (GO) with 2,5,7-trinitro-9-oxo-fluorenone-4-carboxylic acid (TNF-COOH) moieties, via simple synthetic routes. The yielded molecule N-[(carbamoyl-GO)ethyl]-N′-[(carbamoyl)-(2,5,7-trinitro-9-oxo-fluorene)] (GO-TNF) was thoroughly characterized and it was shown that it presents favorable highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) energy levels to function as a bridge component between the polymeric donor poly({4,8-bis[(2-ethylhexyl)oxy]benzo[1,2-b:4,5-b′]dithiophene-2,6-diyl}{3-fluoro-2-[(2-ethylhexyl)carbonyl] thieno[3,4-b]thiophenediyl}) (PTB7) and the fullerene derivative acceptor [6,6]-phenyl-C71-butyric-acid-methylester (PC71BM). In this context, a GO-TNF based ink was prepared and directly incorporated within the binary photoactive layer, in different volume ratios (1%–3% ratio to the blend) for the effective realization of inverted ternary organic solar cells (OSCs) of the structure ITO/PFN/PTB7:GO-TNF:PC71BM/MoO3/Al. The addition of 2% v/v GO-TNF ink led to a champion power conversion efficiency (PCE) of 8.71% that was enhanced by ~13% as compared to the reference cell.
29
Xie, Yue, Ya Gao, Jianjun Jia, Xiaohong Wang, Zhenfu Wang e Hengge Xie. "Utility of AD8 for Cognitive Impairment in a Chinese Physical Examination Population: A Preliminary Study". Scientific World Journal 2014 (2014): 1–4. http://dx.doi.org/10.1155/2014/804871.
Abstract (sommario):
Objective. To investigate the utility of AD8 for cognitive impairment in a Chinese physical examination population.Methods. Military cadres who took routine physical examination in Chinese PLA General Hospital from Jan 1, 2013, to Dec 31, 2013, were subjected to AD8 scale. Individual information such as age, gender, and education was also collected. All data were analyzed by SPSS 19.0.Results. 1544 subjects were enrolled in this study with mean age 75.4 ± 10.6 years. The subjects who scored 0 to 8 of AD8 scale were 1015, 269, 120, 60, 30, 14, 19, 8, and 9, respectively. Corresponding proportions were 65.7%, 17.4%, 7.8%, 3.9%, 2.0%, 0.9%, 1.2%, 0.5%, and 0.6%, respectively. The endorsement prevalence of 8 questions was 5.6%, 9.2%, 6.6%, 9.2%, 4.8%, 4.5%, 8.9%, and 24.1%, respectively. The endorsement prevalence of question 8 was significantly higher than others (P<0.05). 260 subjects were scored equal to or greater than 2. The abnormal rate was 16.9%. All the participants were stratified into 9 groups by age; the prevalence of dementia was highly correlated with age (P<0.01).Conclusion. AD8 scale is a convenient and effective tool for cognitive screening in routine physical examination population.
30
Ningrum, Rahma Farah, Riki Ruli A. Siregar e Darma Rusjdi. "Fuzzy mamdani logic inference model in the loading of distribution substation transformer SCADA system". IAES International Journal of Artificial Intelligence (IJ-AI) 10, n. 2 (1 giugno 2021): 298. http://dx.doi.org/10.11591/ijai.v10.i2.pp298-305.
Abstract (sommario):
<span id="docs-internal-guid-152e332e-7fff-7073-a541-1d420decb47b"><span>The research objective of supervisory control and data acquisition (SCADA), with fuzzy Mamdani logic simulation on the loading section of distribution transformer substations. Data acquisition is available when saving SAIFI SAIDI data and storing the results of monitoring equipment. The method used is Mamdani fuzzy logic, there are two input variables, namely current and voltage devices. The membership function in Mamdani fuzzy logic has been created based on the input current and voltage variables. Currently: parameter {0, 600} low is created {0, 350, 450, 600}, normal {400-650} parameter is created {400, 500, 550, 650}, parameter high {≥600} is created {600, 650, 750, 1000}, when determining the voltage: low {≤10.5} parameters {0 4 7 10.5}, normal {9-14} parameters {9, 10, 13, 14} and high {≥13} - parameters {13, 14, 15, 16}. Based on the results of the Mamdani logic rule test on the output current containing a transformer and a voltage sensor, the results obtained are IF (normal current; (630) AND voltage (high); (13.2) (high load transformer). The components in the simulation tool include miniature substations made with the 1A travel substation model, 3A substation as the main substation, the relay as distribution substation as the monitoring application. Telestatus and Telecontrol use a microcontroller. Initial scenario. After substation is resumed, data is stored after downtime, service life, duration, and data period. Initial scenario After substation is resumed, data is stored after downtime, service life, duration, and data period.</span></span>
31
Kadiri, Helen Ejiro, e Leleji Irene. "Ficus Capensis Modulates Oxidative Stress Parameters in Cyanide Induced Rats". Sokoto Journal of Medical Laboratory Science 7, n. 1 (10 giugno 2022): 124–30. http://dx.doi.org/10.4314/sokjmls.v7i1.16.
Abstract (sommario):
The sub-acute effect of F. capensis was assessed on the oxidative stress markers in the kidney of rats following exposure to cyanide. These effects were compared to those of sodium thiosulphate (Na2S2O3), a classical antidote of cyanide toxicity. The rats were divided into 9 groups of 5 animals each. Group 1: rats (normal control); Group 2: rats were exposed to 3mg/kg of cyanide; group 3: cyanide induced rats that received 660mg/kg sodium thiosulphate pentahydrate and 6.6 mg/kg sodium nitrite; group 4 and 5: rats exposed to cyanide, pre-treated with 200 and 400mg/kg extract respectively; group 6 and 7: rats were exposed to cyanide, post-treated with 200 and 400 mg/kg extract respectively; group 8 and 9: rats exposed to cyanide, co-treated with 200 and 400mg/kg extract respectively. The study lasted for 28 days after which the rats were sacrificed and kidney homogenates were collected for biochemical assays. The level of malondialdehyde (MDA) in Groups 2 rats (367.99±17.73Units/g tissue) was significantly increased in the kidney relative to the control (148.92±4.50 Units/g tissue). This was accompanied with a decrease in antioxidant enzymes Superoxide Dismutase (SOD) (7.81±2.45 Units/g of tissue), Catalase (CAT) (34.33±1.73 Units/g of tissue), compared with the control (16.18±0.42 units/g of tissue) and 64.82±8.91 units/g tissue respectively. Pre-administration of F. capensis extract significantly increased these antioxidant extract reduced lipid peroxidation in the kidney and increased antioxidant status of animals exposed to cyanide and was more effective at 400 mg/kg dose.
32
Duckett, Bob. "The Seventeenth Century Literature Handbook2011274Marshall Grossman. The Seventeenth Century Literature Handbook. Malden, MA, and Oxford: Wiley‐Blackwell 2011. xxii + 405 pp., ISBN: 978 0 631 22090 9 (hbck); 978 0 631 22091 6 (pbck) £60/$99.95 (hbck); £19.99/$39.95 (pbck) Blackwell Literature Handbooks". Reference Reviews 25, n. 6 (9 agosto 2011): 32–33. http://dx.doi.org/10.1108/09504121111156120.
33
Geiger, Jessica Lyn, Gregory A. Daniels, Ezra E. W. Cohen, Joy Yang Ge, Burak Gumuscu, Ramona F. Swaby e Anne Lynn S. Chang. "KEYNOTE-630: Phase 3 study of adjuvant pembrolizumab versus placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma." Journal of Clinical Oncology 37, n. 15_suppl (20 maggio 2019): TPS9597. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.tps9597.
Abstract (sommario):
TPS9597 Background: Among patients with high-risk, locally advanced (LA) cutaneous squamous cell carcinoma (cSCC) who receive current standard-of-care surgical resection and adjuvant radiotherapy, ~40-50% develop local recurrence and regional metastasis ( J Clin Oncol. 2018;36:1275-1283). Recent data suggest that programmed death 1 inhibitors such as pembrolizumab may provide a well-tolerated, effective, and durable response in patients with LA or metastatic cSCC. To evaluate the efficacy and safety of adjuvant pembrolizumab in patients with high-risk LA cSCC, the randomized, double-blind, placebo-controlled phase 3 KEYNOTE-630 trial (NCT03833167) will be conducted. Methods: After surgical resection and radiotherapy for high-risk LA cSCC, eligible patients will be randomly assigned 1:1 to intravenous pembrolizumab (400 mg Q6W) or placebo for up to 9 cycles (~1 year), with radiographic imaging at least every 12 weeks until year 2 and then every 6 months until the end of year 5 to assess treatment response. Eligibility criteria will include age ≥18 years, histologically confirmed LA cSCC with ≥1 high-risk feature at the primary site of malignancy, macroscopic resection with or without microscopic positive margins, completed adjuvant radiotherapy, disease free ≤28 days from randomization, and ECOG performance status 0-1. Treatment will be discontinued at disease recurrence, start of new anticancer treatment, unacceptable toxicity, intercurrent illness that prevents treatment, pregnancy, investigator or patient decision to withdraw, or administrative reasons that require treatment cessation. After the first disease recurrence, all patients who meet crossover or retreatment criteria may receive pembrolizumab 400 mg Q6W for up to 18 cycles. Adverse events will be monitored throughout the study and graded according to the NCI CTCAE, version 4.0. The primary efficacy end point will be investigator-assessed and biopsy-confirmed recurrence-free survival. Secondary end points will be overall survival, health-related quality of life, and safety. Recruitment is ongoing in 19 countries and will continue until approximately 570 patients are enrolled. Clinical trial information: NCT03833167.
34
Ceglarek, Bernadeta B., Lech J. Konopka, Anna Sikorska, Kinga Kos, Jerzy Holowiecki, Malgorzata Kopera, Grazyna Bober et al. "Gleevec Therapy in Advanced Phases of the Cml - Polish Study Report." Blood 104, n. 11 (16 novembre 2004): 4701. http://dx.doi.org/10.1182/blood.v104.11.4701.4701.
Abstract (sommario):
Abstract Accelerated phase marks the onset of advanced rapidly progressive chronic myelogenous leukaemia (CML) and generally leads finally to a fatal blast crisis (BC) within 6 months. Gleevec (imatinib mesylate) as a potent tyrosine kinase inhibitor has demonstrated significant activity in chronic phase (CP) of CML. Because of the observed activity and favorable tolerability of Gleevec and because of the limited treatment options available to these patients we have introduced Gleevec in CML patients meeting rigorous criteria for acceleration and blast crisis phase of CML. PATIENTS: MALE - 31 and FEMALE - 20 were eligible for inclusion in this study if they were at least 18 years old and had a diagnosis of Ph+ CML (AP; BC) confirmed by cytology, histology, cytogenetic and molecular analyses. Characteristics CML patients (AP-accelerated phase; BC-blast crisis phase) is showed in table 1. Table 1- Demographics, Disease History and Characteristics of CML Patients. 1 Duration time of CML-yr 3.8 (1–4.5) 3.7 (0.7–5.1) Prior therapy -n(%) 100% 100% combined Chemotherapy 10 (33) 18 (86) BMT 2 (6.6) 0 Sokal’s score >0.8 16 (53) 15 (71) PLT (x 109/L) 100.0–300.0 11 (37) 8 (38) >300.0 15 (50) 4 (19) Blasts in peripheral blood (%) median 9 34 range 4–20 31–80 Blasts in bone marrow (%) range 10–25 32–78 HGB (g%) median 6.24 6.12 range 5.0–9.4 4.4–10.0 Gleevec dosage AP BC 300mg: n (%) 1 (3.3) 1 (4.8%) 400 mg: n (%) 4 (13.3) 1 (4.8) 600–800 mg: n (%) 25 (83.4) 19 (90.4) Duration of treatment (months) AP BC median 31.64 40.0 range 1–98 0.5–91 Patients received Gleevec 300–800 mg orally daily (table 2). Clinical evaluation of Gleevec therapy was determined by the rate of sustained haematological response (lasting >= 4 weeks) The results of Gleevec therapy are showed in table 2. Table 2 - Haematologic Response in Patients with AP & BC Phase after Gleevec Treatment Response AP BC 2 CHR 25 (83.3%) 4 (19.0%) Cytogenetic response Major : 5 (16.7%) 1 (4.8%) CCR 2 (6.7%) 0 PCR 3 (10.0%) 1 (4.8%) Minimal 11 (36.7%) 1.4.8%) No response 9 (30%) 18 (85.6%) BMT performed 5 (16.7%) 2 (9.6%) after Gleevec therapy (months) 6–12 7–13 The most often observed side effects were irst few months ( neutropenia, thrombocytopenia, weakness, bone and muscles pain, headache, nausea, vomiting, diarrhoea, legs’ oedema, deaths (6.3% – 27.3%). Conclusions: Imatinib as a single agent is well tolerated and has substantial activity in the accelerated phase of CML. The overall response rate in these cases was 83%. Imatinib as a single agent is well tolerated and has substantial activity in the accelerated phase of CML. The overall response rate in these cases was 83%. Imatinib as a single agent is well tolerated and has substantial activity in the accelerated phase of CML. The overall response rate in these cases was 83%. 5 pts. out of these 30 patients are still in the chronic phase after 10 to 32 months of follow-up. In 4 ( 19%) out of 21 patients with BC the improvement after Gleevec therapy was short and transient mainly due to advanced stage of disease.
35
Saunders, Cláudia, Maria do Carmo Leal, Paulo Augusto Ribeiro Neves, Patricia de Carvalho Padilha, Letícia Barbosa Gabriel da Silva e Arthur Orlando Corrêa Schilithz. "Determinants of gestational night blindness in pregnant women from Rio de Janeiro, Brazil". Public Health Nutrition 19, n. 5 (9 giugno 2015): 851–60. http://dx.doi.org/10.1017/s1368980015001846.
Abstract (sommario):
AbstractObjectiveTo describe the prevalence and determinants of gestational night blindness in pregnant women receiving care in a hospital in Rio de Janeiro, Brazil.DesignCross-sectional study of pregnant and postpartum women receiving care in a public hospital in Rio de Janeiro from 1999 to 2001 (group I; n 225) or from 2005 to 2008 (group II; n 381). Night blindness was identified through a standardized and validated interview (WHO, 1996). The determinants of gestational night blindness were identified through a hierarchical logistic regression model.SettingPublic maternity hospital in Rio de Janeiro, RJ, Brazil.SubjectsAdult pregnant and postpartum women (n 606), aged ≥20 years.ResultsThe prevalence of gestational night blindness was 9·9 %. The final model revealed that not living in the South Zone of Rio de Janeiro (distal level: adjusted OR=1·846; 95 % CI 1·002, 3·401), belonging to group I (intermediate level: adjusted OR=2·183; 95 % CI 1·066, 4·471) and for the proximal level, having a history of abortion (adjusted OR=2·840; 95 % CI 1·134, 7·115) and having anaemia during the first and second trimesters of pregnancy (adjusted OR=3·776; 95 % CI 1·579, 9·029) were determinants of gestational night blindness.ConclusionGestational night blindness should be assessed for during the prenatal care of all pregnant women, especially those living in deprived areas of the city and/or who have a history of abortion or anaemia. Nutritional monitoring is recommended during pregnancy to control gestational night blindness.
36
Samura, Lisa, Cahaya Rosyidan, Mustamina Maulani, Suryo Prakoso, Bayu Satiyawira, Maman Djumantara, Onnie Ridaliani, Mulia Ginting e Mohammad Apriniyadi. "Physical property comparison of polymeric KCl sludge composition and polyamine at different temperatures". IOP Conference Series: Earth and Environmental Science 1339, n. 1 (1 maggio 2024): 012020. http://dx.doi.org/10.1088/1755-1315/1339/1/012020.
Abstract (sommario):
Abstract Drilling mud is a fluid used to assist the drilling process. The composition and physical properties of the mud greatly influence a drilling operation. Drilling operations that penetrate formations with shale content have the potential to experience drilling problems related to shale hydration. To get a good ability to prevent shale hydration, mud is added with polymeric and polyamine KCl additives (shale inhibitors) with the aim of stabilizing shale in contact with drilling fluid, as well as preventing drill cuttings from forming colloids. The results obtained in the KCl polymer mud composition at temperatures of 80°F, 250°F, and 300°F for mud weight were 9.3 ppg, 9.1 ppg, and 9 ppg, respectively. Funnel viscosity was 40 sec/qt, 36 sec/qt, and 34 sec/qt. Tap rates were 4.8 cc, 6 cc, and 6.6 cc. Mud cake remained at 1 mm and pH also remained at 9. While the results obtained on polyamine mud composition at temperatures of 80°F, 250°F, and 300°F for mud weight were 9.2 ppg, 8.9 ppg, and 8.8 ppg, respectively. Funnel viscosity was 26 sec/qt, 20 sec/qt, and 17 sec/qt. Tap rate of 10 cc, 13.8 cc, and 15 cc. Mud cake of 1 mm, 2 mm, and 2 mm. pH remains at 9. The data obtained shows that the results of the physical properties of polymeric KCl mud are better than polyamine mud.
37
Riaño, K., e O. Briones. "Leaf physiological response to light environment of three tree fern species in a Mexican cloud forest". Journal of Tropical Ecology 29, n. 3 (maggio 2013): 217–28. http://dx.doi.org/10.1017/s0266467413000230.
Abstract (sommario):
Abstract:Abundance and physiology of three understorey tree fern species were compared in a Mexican cloud forest. We hypothesized that the distribution of species would be associated with canopy openness and leaf physiological characteristics. In gullies (1–2% full sun), Alsophila firma was abundant, Cyathea divergens was distributed in moderately open places (4–9%), and Lophosoria quadripinnata preferred more open canopy (9–30%). Although 11 leaf traits of five plants of each species growing under closed and open canopies over 1 y did not differ within species, there were significant interspecific differences. Alsophila firma had comparatively low maximum electron transport rate ETRmax (26.8 ± 1.81 μmol m−2 s−1) and ETR light saturation point (ETRLSP: 261 ± 36.1 μmol m−2 s−1), high specific leaf area (SLA), thin leaves and decreased quantum yield during a leaf desiccation experiment. Cyathea divergens had relatively high maximum quantum yield (0.84 ± 0.004), ETRmax (37.3 ± 1.8 μmol m−2 s−1) and ETRLSP (409 ± 40.0 μmol m−2 s−1). Lophosoria quadripinnata had comparatively thick leaves, low SLA, high predawn water potential, high density (606 ± 25.5 mm−2) and small length (0.026 ± 0.002 mm) stomata. The results support the hypothesis that light sensitivity shapes tree fern distribution in the cloud forest.
38
Rozier, John Paul. "Colin Baker. Development Governor: A Biography of Sir Geoffrey Colby. London: British Academic Press; distributed by St. Martin's Press, New York, N.Y. 1994. Pp. xiv, 407. $59.50. ISBN 1-85043-616-9." Albion 27, n. 1 (1995): 182–84. http://dx.doi.org/10.1017/s0095139000019190.
39
Barbosa, Tiago C., Andreij C. Gadelha, Douglas A. A. Ohlberg, Kenji Watanabe, Takashi Taniguchi, Gilberto Medeiros-Ribeiro, Ado Jorio e Leonardo C. Campos. "Raman spectra of twisted bilayer graphene close to the magic angle". 2D Materials 9, n. 2 (1 febbraio 2022): 025007. http://dx.doi.org/10.1088/2053-1583/ac4af9.
Abstract (sommario):
Abstract In this work, we study the Raman spectra of twisted bilayer graphene samples as a function of their twist-angles (θ), ranging from 0.03° to 3.40°, where local θ are determined by analysis of their associated moiré superlattices, as imaged by scanning microwave impedance microscopy. Three standard excitation laser lines are used (457, 532, and 633 nm wavelengths), and the main Raman active graphene bands (G and 2D) are considered. Our results reveal that electron–phonon interaction influences the G band’s linewidth close to the magic angle regardless of laser excitation wavelength. Also, the 2D band lineshape in the θ < 1° regime is dictated by crystal lattice and depends on both the Bernal (AB and BA) stacking bilayer graphene and strain soliton regions (SP) (Gadelha et al 2021 Nature 590 405–9). We propose a geometrical model to explain the 2D lineshape variations, and from it, we estimate the SP width when moving towards the magic angle.
40
Younas, Mariam, Danielle Osterholzer, Brandon R. Flues, Carlos Rios-Bedoya, Philip McDonald, Ghassan Bachuwa, Michael W. Tupper e Michael Jaggi. "549. Monoclonal Antibody Therapy for COVID-19 Infection in Michigan: The Flint Experience". Open Forum Infectious Diseases 8, Supplement_1 (1 novembre 2021): S376—S377. http://dx.doi.org/10.1093/ofid/ofab466.748.
Abstract (sommario):
Abstract Background Bamlanivimab (BAM), a neutralizing IgG1 monoclonal antibody (mAb), received emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) for treatment of mild to moderate COVID-19 infection in patients 12 years of age and older weighing at least 40 kg at high risk for progressive and severe disease on Nov 10, 2020. The purpose of this study is to describe our experience with this treatment modality. Methods Hurley Medical Center (HMC), is a 443-bed inner city teaching hospital in Flint, MI. HMC administered its first BAM infusion on Nov 19, 2020. Through April 30, 2021, 407 patients with confirmed SARS-CoV-2 infection, received a mAb infusion. 62/407 patients received the combination mAb therapy of BAM + Etesevimab, as the EUA for BAM monotherapy was revoked on 04/16/21. We retrospectively collected basic demographic data and hospitalization to our facility within 14 days of receiving mAb therapy on these patients. Results During the 5.5 month study period, patients receiving mAb therapy at HMC had a mean age of 56 years (yrs) (± standard deviation) (± 15.4) and a mean Body Mass Index (BMI) of 34 kg/m² (± 8.5) (Tables 1,2). African Americans (AA) comprised 48% (194/407) (Table 3) and females comprised 54% (220/407) of the cohort. 6% (25/407) of the patients required hospitalization within 14 days of mAb infusion, had a mean age of 58 yrs (± 17) (p-value 0.62) and a mean BMI of 32 kg/m² (± 9) (p-value 0.33). Females and AA comprised 56% (14/25) and 48% (12/25) of this subgroup respectively (p-value 1.0). No deaths were reported within 30 days of infusion in this cohort. Conclusion Previously published reports cite a hospitalization rate in untreated high-risk COVID-19 infected patients of 9-15%. During the period of study, the county hospitalization rate and county mortality rate for all comers with COVID-19 was 6.6% and 2.7% respectively while our high risk cohort had a hospitalization rate of 6% and with no deaths reported. Our cohort had much lower rates of hospitalization and death than would be expected especially in a group which comprised of 48% AA in an underserved area. mAb therapy seems to have a protective effect with significant reduction in the hospitalization and mortality rate among high-risk patients with COVID-19 infection and should be prioritized for administration. Disclosures All Authors: No reported disclosures
41
Darpo, Borje, Anita F. Das, Daniel Stein, Jennifer Schranz e Steven P. Gelone. "684. Cardiac Safety in Adults with Community-Acquired Bacterial Pneumonia (CABP) Treated with Lefamulin (LEF) or Moxifloxacin (MOX): Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results". Open Forum Infectious Diseases 6, Supplement_2 (ottobre 2019): S311. http://dx.doi.org/10.1093/ofid/ofz360.752.
Abstract (sommario):
Abstract Background Preclinical data suggest potential effects of LEF on cardiac interval parameters. We therefore assessed LEF cardiac safety from the LEAP 1/2 trials. Methods In LEAP 1, PORT III–V patients received LEF 150mg IV q12h for 5–7 days or MOX 400mg IV q24h for 7 days, with optional IV-to-oral switch (600mg LEF q12h or 400 mg MOX q24h). In LEAP 2, PORT II–IV patients received oral LEF 600mg q12h for 5 days or oral MOX 400mg q24h for 7 days. Patients with known QT prolongation or on medication with potential to prolong the QT interval were excluded as per MOX label. After 5 minutes of rest in the supine position, triplicate 12-lead ECGs were obtained within a 5-minute interval at Screening in both studies, on Days 1/3 in LEAP 1 (predose and ≤15 minutes after first IV dose), and on Days 1/4 in LEAP 2 (predose and 1–3 hours after first oral dose), and sent to a central ECG reader for adjudication. Results Of 1,282 randomized/treated patients (n = 641/group), 1,274 had baseline (BL) and post-BL ECG data (n = 636 LEF, n = 638 MOX). Consistent with the resolution of infection, ECGs revealed mean reductions of 7–8 beats/minute for both groups in both studies. The largest mean change in QTcF from BL to post-BL was on Day 3 in LEAP 1 (13.6 and 16.4 msec with IV LEF and MOX, respectively) and on Day 4 in LEAP 2 (9.3 and 11.6 msec with oral LEF and MOX, respectively). The proportion of patients meeting potentially important post-BL QTcF values/changes was comparable between treatment groups (table). In the standardized MedDRA query of Torsade de pointes/QT prolongation (broad), the most common treatment-emergent adverse event was ECG QT prolonged (n = 4 LEF, n = 5 MOX). All events were nonserious and mild or moderate in severity. 6 events were considered study drug related (n = 4 LEF, n = 2 MOX). 5 events led to study drug discontinuation (n = 2 LEF, n = 3 MOX). In 2 patients with cardiovascular disease, 1 had ventricular arrhythmia on Day 20 (18 days after last LEF dose) and 1 had cardiac arrest on Day 18 (9 days after last MOX dose); both events were fatal and considered unrelated to study drug by investigator. Conclusion Mild prolongation of the QTcF interval was seen with LEF and MOX, with somewhat smaller effects seen with LEF. Given the small effect, LEF is unlikely to pose a clinically significant risk of ventricular proarrhythmia with appropriate precautions and use. Disclosures All authors: No reported disclosures.
42
Halley, Sleight, Kannan Ramaiyan, James Smith, Robert Ian, Kamil Agi, Fernando H. Garzon e Lok-kun Tsui. "Mixed Potential Electrochemical Sensors for Natural Gas Leak Detection – Field Testing of Portable Sensor Package". ECS Meeting Abstracts MA2023-01, n. 52 (28 agosto 2023): 2604. http://dx.doi.org/10.1149/ma2023-01522604mtgabs.
Abstract (sommario):
According to the EPA, methane (CH4) emissions from oil and gas infrastructure accounted for 211 million metric tons of CO2 equivalent in 2020 [1]. Actual emissions may exceed this by a factor of three [2]. Current natural gas leak detection technologies largely consist of optical sensors such as IR spectrometers [3]. Optical sensors have high sensitivity, but the high cost and fragility of these sensors limit practical applications and continuous monitoring in the field. Mixed potential electrochemical sensors (MPES) are low cost, robust, selective and sensitive, making them a viable option for continuous natural gas leak detection [4]. While we have previously reported on the development of these sensors for natural gas detection in the laboratory, it is necessary to evaluate how these sensors perform in relevant environments. The MPES device consists of La0.87Sr0.13CrO3 (LSC), indium tin oxide (ITO, In2O3 90 wt%, SnO2 10 wt%), and Au sensing electrodes with a Pt pseudo-reference electrode, bridged by 3 mol% YSZ solid electrolyte. A low ionic conductivity magnesia stabilized zirconia (MSZ) substrate is used to enhance sensitivity with a demonstrated limit of detection (LOD) of < 40 ppm. The sensor is integrated with an internet of things (IoT) data collection and transmission package developed by SensorComm Technologies. Field testing was performed at Colorado State University’s Methane Emission Technology Evaluation Center (METEC). The sensors’ capability of detecting buried pipeline leaks was investigated by varying the leak rate from 7.2 SLPM to 37 SLPM, lateral sensor distance from 0 meters to 3 meters, and vertical distance from 0 meters to 0.28 meters (Figure 1). Machine learning methods were applied to a training dataset collected in the laboratory to quantify the CH4 concentration. These results serve as a first demonstration that a low-cost mixed potential electrochemical sensor system can successfully detect underground pipeline emissions and quantify CH4 concentrations that are in agreement with previously published results [6] collected using more complex and costly methods. References: [1] O. US EPA, “Estimates of Methane Emissions by Segment in the United States,” Aug. 27, 2018. https://www.epa.gov/natural-gas-star-program/estimates-methane-emissions-segment-united-states (accessed Dec. 08, 2022). [2] A. J. Marchese et al., “Methane Emissions from United States Natural Gas Gathering and Processing,” Environ. Sci. Technol., vol. 49, no. 17, pp. 10718–10727, Sep. 2015, doi: 10.1021/acs.est.5b02275. [3] T. Aldhafeeri, M.-K. Tran, R. Vrolyk, M. Pope, and M. Fowler, “A Review of Methane Gas Detection Sensors: Recent Developments and Future Perspectives,” Inventions, vol. 5, no. 3, Art. no. 3, Sep. 2020, doi: 10.3390/inventions5030028. [4] F. H. Garzon, R. Mukundan, and E. L. Brosha, “Solid-state mixed potential gas sensors: theory, experiments and challenges,” Solid State Ion., vol. 136–137, pp. 633–638, Nov. 2000, doi: 10.1016/S0167-2738(00)00348-9. [5] S. Halley, L. Tsui, and F. Garzon, “Combined Mixed Potential Electrochemical Sensors and Artificial Neural Networks for the Quantificationand Identification of Methane in Natural Gas Emissions Monitoring,” J. Electrochem. Soc., vol. 168, no. 9, p. 097506, Sep. 2021, doi: 10.1149/1945-7111/ac2465. [6] B. A. Ulrich, M. Mitton, E. Lachenmeyer, A. Hecobian, D. Zimmerle, and K. M. Smits, “Natural Gas Emissions from Underground Pipelines and Implications for Leak Detection,” Environ. Sci. Technol. Lett., vol. 6, no. 7, pp. 401–406, Jul. 2019, doi: 10.1021/acs.estlett.9b00291. Figure 1: Sensor response to various heights above a simulated buried pipeline leak on two successive days of testing (a and b), and estimated CH4 concentrations from sensor data (c). Figure 1
43
Sadati, Nargess, Kristina Jenett-Siems, Karsten Siems, Mohammad Reza Shams Ardekania, Abbas Hadjiakhoondi, Tahmineh Akbarzadeh, Seyed Nasser Ostad e Mahnaz Khanavi. "Major Constituents and Cytotoxic Effects of Ajuga chamaecistus ssp. tomentella". Zeitschrift für Naturforschung C 67, n. 5-6 (1 giugno 2012): 275–81. http://dx.doi.org/10.1515/znc-2012-5-606.
Abstract (sommario):
The n-butanolic fraction of a methanolic extract (80%) from aerial parts of Ajuga chamaecistus ssp. tomentella was analysed using different chromatographic methods. Column (CC) and high-performance liquid chromatography (HPLC) were used for isolation and purifi cation. 13C, 1H NMR, H-H COSY, HSQC, HMBC, and ESI-MS were employed for identifi cation of the compounds isolated from this fraction. The structures of the compounds were determined to be cis-melilotoside (1), trans-melilotoside (2), lavandulifolioside (3), 20-hydroxyecdysone (4), leonoside B (5), martynoside (6), ajugalactone (7), makisterone A (8), and 24-dehydroprecyasterone (9). This is the fi rst report on the presence of cis- and transmelilotoside in Ajuga species. Cytotoxic evaluation of the n-butanolic fraction, cis- and transmelilotoside against cancer (T47D, HT-29, and Caco-2) and normal (NIH 3T3) cell lines by the mitochondrial tetrazolium test (MTT) showed no cytotoxic effects up to 400 μg/mL. The results of this study suggest that melilotoside, phenylethyl glycosides, and phytoecdysteroids are the main constituents of the n-butanolic fraction of Ajuga chamaecistus ssp. tomentella
44
Junipitoyo, Bambang, e Moch Rifai. "Performa Mesin Bensin Berbahan Bakar Ethanol 50 dengan Pengaturan Kompresi Rasio dan Durasi Injeksi". Jurnal Penelitian 2, n. 4 (4 dicembre 2017): 249–53. http://dx.doi.org/10.46491/jp.v2e4.57.249-253.
Abstract (sommario):
Ethanol merupakan bahan bakar yang menghasilkan polutan yang rendah, bahan bakar yang aman, titik nyala etanol tiga kali lebih tinggi dibandingkan bensin dan emisi hidokarbon lebih sedikit. Ethanol 50 merupakan campuran premium 50% - Bioethanol 50% yang mempunyai nilai kalor lebih rendah dari premium. Pengaruh rasio kompresi pada kinerja mesin Bensin dengan 50% bioethanol gasoline bahan bakar dicampur diselidiki pada dinamometer rem air. Sifat bioetanol diukur berdasarkan pada American Society for Testing Material (ASTM) standar. Tujuan penelitian ini adalah mengetahui unjuk kerja mesin bensin yang menggunakan bahan bakar Ethanol E50 dengan pengaturan kompresi rasio dan durasi injeksi. Penelitian dilakukan pada Mesin Bensin 2 silinder 650 cc pada variable speed 2000 - 5000 rpm, metode yang digunakan adalah dengan mengatur kompresi rasio dan durasi injeksi. Kompresi rasio yang digunakan pada penelitian ini sebesar 9 , 10 dan 11. Sedangkan durasi injeksi dilakukan pada digunakan pada penelitian ini sebesar 6 ms, 6,6 ms dan 7,2 ms. Hasil penelitian ini menunjukkan bahwa melalui pengaturan kompresi rasio dan durasi injeksi pada mesin bensin berbahan bakar Ethanol 50, pada kompresi rasio 11 diperoleh kenaikan torsi, daya mengalami kenaikan sebesar 9 %, 4,08% terhadap E50 standar. dibandingkan dengan menggunakan bensin murni pada kompresi rasio 9,6. Sedangkan pengaruh rasio kompresi dan durasi injeksi dengan pada E50 dapat menaikan konsumsi bsfc 2,1% dari E50 Standar dan meningkatkan thermal efisiensi dengan 9,2%.
45
O’Lone, Emma, Martin Howell, Andrea K. Viecelli, Jonathan C. Craig, Allison Tong, Benedicte Sautenet, William G. Herrington et al. "Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals". Nephrology Dialysis Transplantation 35, n. 10 (10 febbraio 2020): 1761–69. http://dx.doi.org/10.1093/ndt/gfaa008.
Abstract (sommario):
Abstract Background Cardiovascular disease (CVD) is a major contributor to morbidity and mortality in people on hemodialysis (HD). Cardiovascular outcomes are reported infrequently and inconsistently across trials in HD. This study aimed to identify the priorities of patients/caregivers and health professionals (HPs) for CVD outcomes to be incorporated into a core outcome set reported in all HD trials. Methods In an international online survey, participants rated the absolute importance of 10 cardiovascular outcomes (derived from a systematic review) on a 9-point Likert scale, with 7–9 being critically important. The relative importance was determined using a best–worst scale. Likert means, medians and proportions and best–worst preference scores were calculated for each outcome. Comments were thematically analyzed. Results Participants included 127 (19%) patients/caregivers and 549 (81%) HPs from 53 countries, of whom 530 (78%) completed the survey in English and 146 (22%) in Chinese. All but one cardiovascular outcome (‘valve replacement’) was rated as critically important (Likert 7–9) by all participants; ‘sudden cardiac death’, ‘heart attack’, ‘stroke’ and ‘heart failure’ were all rated at the top by patients/caregivers (median Likert score 9). Patients/caregivers ranked the same four outcomes as the most important outcomes with mean preference scores of 6.2 (95% confidence interval 4.8–7.5), 5.9 (4.6–7.2), 5.3 (4.0–6.6) and 4.9 (3.6–6.3), respectively. The same four outcomes were ranked most highly by HPs. We identified five themes underpinning the prioritization of outcomes: ‘clinical equipoise and potential for intervention’, ‘specific or attributable to HD’, ‘severity or impact on the quality of life’, ‘strengthen knowledge and education’, and ‘inextricably linked burden and risk’. Conclusions Patients and HPs believe that all cardiovascular outcomes are of critical importance but consistently identify sudden cardiac death, myocardial infarction, stroke and heart failure as the most important outcomes to be measured in all HD trials.
46
Zaizul Ab Rahman, Fauziah Ibrahim e Nasrudin Subhi. "Faktor Keagamaan Yang Mempengaruhi Semangat Perpaduan dalam Kalangan Remaja yang Tinggal di Kawasan Program Perumahan Rakyat (PPR)". global journal al thaqafah 8, n. 1 (31 luglio 2018): 107–14. http://dx.doi.org/10.7187/gjat072018-9.
Abstract (sommario):
Elemen keagamaan dalam semangat perpaduan merupakan unsur penting untuk mengekalkan keharmonian dan kemakmuran dalam kalangan masyarakat pelbagai bangsa di Malaysia. Oleh itu artikel ini disediakan bertujuan untuk mengenalpasti pengaruh faktor-faktor yang mempengaruhi elemen keagamaan dalam semangat perpaduan dalam kalangan remaja yang tinggal di kawasan perumahan rakyat di Malaysia. Kajian dijalankan dengan menggunakan reka bentuk tinjauan keratanlintang secara kuantitatif. Seramai 244 orang remaja yang tinggal di tiga buah kawasan perumahan iaitu di perumahan Rakyat Desa Rejang, Pantai Ria dan Seri Pantai telah dipilih sebagai responden kajian. Data kajian telah dianalisis dengan menggunakan ujian deskriptif dan regresi pelbagai secara stepwise. Analisis deskriptif menunjukkan bahawa majoriti (59.8%) remaja yang tinggal di kawasan perumahan rakyat menunjukkan elemen keagamaan yang sederhana sahaja dan perlu dipertingkatkan. Analisis regrasi pelbagai pula mendapati bahawa faktor kesihatan diri (β=.539, p<.05) adalah petunjuk utama yang mempengaruhi elemen keagamaan dalam semangat perpaduan dalam kalangan remaja. Manakala kombinasi kesihatan diri (β=.405, p<.05) dan tingkah laku prososial (β=.289, p<.05) menyumbang sebanyak 6.6% perubahan tambahan terhadap semangat perpaduan. Faktor hubungan kejiranan dan semangat cintakan Malaysia pula menyumbang sebanyak 3.1% dan 1.4% varians terhadap semangat perpaduan dalam kalangan remaja. Kombinasi keempat-empat faktor peramal tersebut telah menyumbang sebanyak 40.1% varians terhadap semangat perpaduan dalam kalangan remaja yang tinggal di kawasan perumahan rakyat. Hasil kajian memberi implikasi positif kepada pihak-pihak yang berkepentingan dalam usaha untuk menyediakan pelan strategik yang komprehensif dalam menambahbaik program-program yang boleh membina dan menyemarakkan semangat perpaduan dalam kalangan rakyat khasnya remaja yang tinggal di kawasan perumahan rakyat di Malaysia.
47
Mosha, Mary Vincent, Sia E. Msuya, Elizabeth Kasagama, Philip Ayieko, Jim Todd e Suzanne Filteau. "Prevalence and correlates of overweight and obesity among primary school children in Kilimanjaro, Tanzania". PLOS ONE 16, n. 4 (22 aprile 2021): e0249595. http://dx.doi.org/10.1371/journal.pone.0249595.
Abstract (sommario):
Background Prevalence of childhood overweight and obesity in low- and middle-income countries is on the rise. We focused on multiple factors which could influence body mass index. Methods A cross sectional school-based study was conducted in Moshi, Tanzania. Primary school children aged 9–11 years were recruited from 20 schools through a multistage sampling technique. Questionnaires were used to collect information on physical activity and diet by food frequency questionnaire. Height and weight measurements were taken and body mass index z scores for age and sex (BMIZ) calculated using the WHO AnthroPlus. Children were considered thin if BMIZ was <-2 standard deviations and overweight or obese if BMIZ was >1 SD. Information on school policies and environment was obtained from headteachers. Correlates of overweight and obesity were examined using a multinomial multilevel logistic regression. Results A total of 1170 primary school children, of whom 636 (54%) were girls, were recruited from 20 schools. The prevalence of overweight and obesity was 15% overall (overweight 9% and obesity 6%) and most prevalent in urban areas (23%) and in private schools (24%). Moreover, thinness was found to be (10%) overall, most prevalent in rural areas (13%) and in government schools (14%). At school level, residing in urban (adjusted relative risk ratio [aRRR] 3.76; 95% confidence interval [CI] 2.49,5.68) and being in private school (aRRR 4.08; 95% CI 2.66,6.25) were associated with a higher risk of overweight and obesity while availability of playgrounds in schools (aRRR 0.68; 95% CI 0.47, 0.97) was associated with a lower risk of overweight and obesity. At home level, availability of sugary drinks (aRRR 1.52; 95% CI 1.01,2.28) was associated with a higher risk of overweight and obesity. Conclusion Overweight and obesity are common in private schools and in urban settings. Efforts should be taken to ensure availability of playgrounds in schools and encouraging children to engage in physical activities.
48
Kuemmerle, S. C., G. L. Boltinghouse, S. M. Delby, T. L. Lane e R. P. Simondsen. "Automated Assay of Vitamin B-12 by the Abbott IMx® Analyzer". Clinical Chemistry 38, n. 10 (1 ottobre 1992): 2073–77. http://dx.doi.org/10.1093/clinchem/38.10.2073.
Abstract (sommario):
Abstract A nonisotopic assay of vitamin B-12 in human serum or plasma is described, performed with the Abbott IMx analyzer. The sample is first treated at pH > 12.5 to release bound vitamin B-12 and to convert all forms to cyanocobalamin. Next, the analyte is bound, at lower pH, by vitamin B-12-specific binding protein, immobilized to a solid phase of polymeric microspheres. Detection involves monitoring the activity of the tracer enzyme (alkaline phosphatase) coupled to a derivative of cyanocobalamin. Total assay precision is 7.9% for vitamin B-12 at 200 ng/L, 6.6% at 400 ng/L, and 6.7% at 800 ng/L. Assay sensitivity, calculated as 2 SD from the zero calibrator, is 37 (+/- 9) ng/L. The dynamic range extends to 2000 ng/L. Analytical recovery of 300 and 600 ng/L additions of vitamin B-12 to sera with basal concentrations of 30-400 ng/L was 102.5%. Results of the assay correlated well with those of commercially available radioisotope assays. No interference was observed in specimens from patients with pernicious anemia, chronic or acute myelogenous leukemia, or renal failure. Cross-reactivity with cobinamide (1 g/L) was < 0.00003%. Vitamin B-12 measurements for blood specimens drawn into serum, EDTA, or heparinized plasma-collection tubes agreed within 3%.
49
Bajetta, Emilio, Irene Floriani, Maria Di Bartolomeo, Roberto Labianca, Lorenza Landi, Armando Santoro, Rossanna Casaretti et al. "Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer." Journal of Clinical Oncology 30, n. 18_suppl (20 giugno 2012): LBA4001. http://dx.doi.org/10.1200/jco.2012.30.18_suppl.lba4001.
Abstract (sommario):
LBA4001 Background: Following radical resection of gastric or gastroesophageal junction (GEJ) adenocarcinoma, a meta-analysis and randomized studies demonstrated better survival in pts treated with fluoropyrimidine regimens compared to surgery alone. ITACA-S trial is a no-profit, multicenter, randomized, open-label, superiority phase III study aimed at evaluating whether a more intensive postoperative chemotherapy improves efficacy, when replace fluoropyrimidine. Methods: Pts radically resected for gastric or GEJ adenocarcinoma, with ≥D1-lymphadenectomy, node involvement (pN+) or pN0 with pT2b-3-4; within 3-8 weeks after surgery were eligible. Treatment consisted in CPT-11 180 mg/m2 on d1, LV 100 mg/m2 d1-2, 5-FU 400-600 mg/m2 d1-2, q14; for 4 cycles (FOLFIRI regimen) followed by docetaxel 75 mg/m2 d1, cisplatin 75 mg/m2 d1, q 21; for 3 cycles (arm A) vs. LV 100 mg/m2 d1-2, 5-FU 400-600 mg/m2 d1-2, q 14 for 9 cycles (arm B). The primary hypothesis on disease-free survival (DFS) requires 636 events (first recurrence or death) to detect an hazard ratio (HR) of 0.80, with 2-sided 5% significance level for the log-rank test and a power of 80%. Results: From February 2005 to August 2009, 1,106 pts were randomized and 1,100 were analyzed (562 arm A, 538 arm B; 6 major violations) by 123 Italian centers. By March 2012, with a median follow-up of 49 months (quartile range: 36-62) we observed 558 events for DFS (HR 0.98; 95%CI 0.83-1.16;p=0.83) accounting for 88% of the target number and 440 deaths (HR: 1.00; 95%CI 0.83-1.20;p=0.98). Toxicity was consistent with literature. Given the data observed, both under the original hypothesis and the current trend, the probability to reach a statistically significant results at the target events is <0.0001. Conclusions: Adjuvant chemotherapy in gastric cancer with more intensive regimen did not result in a significant prolongation of DFS and OS when compared to bolus/infusion FU/LV regimen.
50
O'Sullivan, David. "Book review: Wilson, J.P. and Fotheringham, A.S., editors 2007: The handbook of geographic information science. Oxford: Blackwell. 634 pp. £60/US$99.95/AU$165.95 cloth, £29.99/ US$54.95/AU$68.95 paper ISBN: 978 1 405 10795 2 cloth, 978 1 405 10796 9 paper". Progress in Human Geography 33, n. 3 (26 maggio 2009): 434–35. http://dx.doi.org/10.1177/03091325090330031607.